Joseph Schwartz
Stock Analyst at Leerink Partners
(4.17)
# 458
Out of 5,161 analysts
154
Total ratings
36.96%
Success rate
21.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.46 | +117.39% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $21.71 | +222.43% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.37 | +0.90% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $59.90 | +167.11% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $10.02 | +39.72% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.98 | +103.89% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $59.07 | +1.57% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $14.37 | +11.34% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $16.94 | +254.19% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $57.60 | +99.65% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $36.51 | +141.03% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $17.04 | -11.97% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $17.38 | +15.07% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $139.52 | -17.57% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $7.63 | +57.27% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $51.84 | -45.98% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $27.55 | +45.19% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $5.44 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $7.71 | +55.64% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.39 | +1,967.72% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $63.36 | -24.24% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $26.38 | -31.77% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $72.34 | -53.00% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $229.01 | -28.82% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $6.15 | +436.59% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.14 | +412.82% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $29.94 | +0.20% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $95.42 | -68.56% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.72 | +597.67% | 2 | Sep 26, 2017 |
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.46
Upside: +117.39%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $21.71
Upside: +222.43%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.37
Upside: +0.90%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $59.90
Upside: +167.11%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $10.02
Upside: +39.72%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.98
Upside: +103.89%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $59.07
Upside: +1.57%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $14.37
Upside: +11.34%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $16.94
Upside: +254.19%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $57.60
Upside: +99.65%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $36.51
Upside: +141.03%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $17.04
Upside: -11.97%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $17.38
Upside: +15.07%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $139.52
Upside: -17.57%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.63
Upside: +57.27%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $51.84
Upside: -45.98%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $27.55
Upside: +45.19%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $5.44
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $7.71
Upside: +55.64%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.39
Upside: +1,967.72%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $63.36
Upside: -24.24%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $26.38
Upside: -31.77%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $72.34
Upside: -53.00%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $229.01
Upside: -28.82%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $6.15
Upside: +436.59%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.14
Upside: +412.82%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $29.94
Upside: +0.20%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $95.42
Upside: -68.56%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.72
Upside: +597.67%